Heparin, urokinase, and ancrod alter neutrophil function Julie A. Freischlag, MD, Michael D. Colburn, MD, William J. Quiñones-Baldrich, MD, Wesley S. Moore, MD Journal of Vascular Surgery Volume 16, Issue 4, Pages 565-574 (October 1992) DOI: 10.1016/0741-5214(92)90164-4 Copyright © 1992 Society for Vascular Surgery and the North American Chapter, International Society for Cardiovascular Surgery Terms and Conditions
Fig. 1 Chart shows effect of tested doses of each agent on production of superoxide anion by activated human PMNs at concentration of 2 × 106 cells/ml. Journal of Vascular Surgery 1992 16, 565-574DOI: (10.1016/0741-5214(92)90164-4) Copyright © 1992 Society for Vascular Surgery and the North American Chapter, International Society for Cardiovascular Surgery Terms and Conditions
Fig. 2 Chart shows effect of tested doses of each agent on chemotaxis of human PMNs at a concentration of 2 × 106 cells/ml. Serum from corresponding subject for each experiment was used as chemoattractant. Asterisks denote statistical significance (p < 0.01) compared with control. Journal of Vascular Surgery 1992 16, 565-574DOI: (10.1016/0741-5214(92)90164-4) Copyright © 1992 Society for Vascular Surgery and the North American Chapter, International Society for Cardiovascular Surgery Terms and Conditions
Fig. 3 Chart shows effect of tested doses of each agent on phagocytosis of opsonized zymosan by human PMNs at concentration of 2 × 106 cells/ml. Serum from corresponding subject for each experiment was used to opsonize zymosan particles. Asterisks denote statistical significance (*p < 0.01; **p < 0.05) compared with control. Journal of Vascular Surgery 1992 16, 565-574DOI: (10.1016/0741-5214(92)90164-4) Copyright © 1992 Society for Vascular Surgery and the North American Chapter, International Society for Cardiovascular Surgery Terms and Conditions